1. Núñez FP, Quera PR, Gomollón F. Primary sclerosing cholangitis and inflammatory bowel disease: intestine–liver interrelation. Gastroenterol Hepatol 2019; 42: 316-25.
2.
Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet (London, England) 2018; 391: 2547-59.
3.
Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transplant 2008; 14: 181-5.
4.
Buchholz BM, Lykoudis PM, Ravikumar R, et al. Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients. World J Gastroenterol 2018; 24: 3171-80.
5.
Krugliak Cleveland N, Rubin DT, Hart J, et al. Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol 2018; 16: 68-74.
6.
Filipec Kanizaj T, Mijic M. Inflammatory bowel disease in liver transplanted patients. World J Gastroenterol 2017; 23: 3214-27.
7.
Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017; 152: 1975-84.e8.
8.
Snook JA, Chapman RW, Sachdev GK, et al. Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J Hepatol 1989; 9: 36-41.
9.
Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. Semin Immunopathol 2009; 31: 383-97.
10.
Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet (London, England) 2002; 360: 1943-4.
11.
Navaneethan U, Choudhary M, Venkatesh PGK, et al. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012; 35: 1054-63.
12.
Fattahi MR, Malek-Hosseini SA, Sivandzadeh GR, et al. Clinical course of ulcerative colitis after liver transplantation in patients with concomitant primary sclerosing cholangitis and ulcerative colitis. Inflamm Bowel Dis 2017; 23: 1160-7.
13.
Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992; 215: 595-8.
14.
Gelley F, Miheller P, Péter A, et al. Activity of ulcerative colitis before and after liver transplantation in primary sclerosing cholangitis: the Hungarian experience. Transplant Proc 2012; 44: 2164-5.
15.
Papatheodoridis GV, Hamilton M, Mistry PK, et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-44.
16.
Jørgensen KK, Grzyb K, Lundin KEA, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012; 18: 536-45.
17.
Villamil A, De Paula JA, Galdame O, et al. Clinical course of inflammatory bowel disease in patients transplanted for primary sclerosing cholangitis. Acta Gastroenterol Latinoam 2008; 38: 252-9.
18.
Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-6.
19.
Gauss A, Sauer P, Stiehl A, et al. Evaluation of biliary calprotectin as a biomarker in primary sclerosing cholangitis. Medicine (Baltimore) 2016; 95: e3510.
20.
Pavlidis P, Joshi D, El Sherif Y, et al. Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease. Frontline Gastroenterol 2022; 13: 497-502.
21.
Arar A, Scott F, Click B, et al. P250 The impact of primary sclerosing cholangitis (PSC) on fecal calprotectin assessment in individuals with inflammatory bowel disease (IBD). J Crohn’s Colitis 2023; 17: i400-2.
22.
Ayling RM, Kok K. Fecal calprotectin. Adv Clin Chem 2018; 87: 161-90.
23.
Fukunaga S, Kuwaki K, Mitsuyama K, et al. Detection of calprotectin in inflammatory bowel disease: fecal and serum levels and immunohistochemical localization. Int J Mol Med 2018; 41: 107-18.
24.
Fu W, Fu H, Ye W, et al. Peripheral blood neutrophil-to-lymphocyte ratio in inflammatory bowel disease and disease activity: a meta-analysis. Int Immunopharmacol 2021; 101: 108235.
25.
Mulita F, Verras GI, Bouchagier K, et al. Butyrylcholinesterase levels as a predictive factor of septic complications development in the postoperative period of colorectal patients: univariate analysis and predictive modeling. Eur J Surg Oncol 2023; 49: E15.
26.
Panos G, Mulita F, Akinosoglou K, et al. Risk of surgical site infections after colorectal surgery and the most frequent pathogens isolated: a prospective single-centre observational study. Med Glas (Zenica) 2021; 18: 438-43.
27.
Mulita F, Liolis E, Akinosoglou K, et al. Postoperative sepsis after colorectal surgery: a prospective single-center observational study and review of the literature. Gastroenterology Rev 2022; 17: 47-51.
28.
Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002; 35: 380-4.
29.
Jørgensen KK, Lindström L, Cvancarova M, et al. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 517-23.
30.
Osiecki M, Kierkuś J, Pawłowska J, et al. The course of ulcerative colitis after pediatric liver transplantation for sclerosing cholangitis. Transplant Proc 2021; 53: 244-9.
31.
Puolanne AM, Qadri S, Vesterinen T, et al. Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin? Scand J Gastroenterol 2022; 57: 1304-11.
32.
Røseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993; 28: 1073-6.
